

IDS Form PTO/SB/06: Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,496
		Filing Date	December 20, 2004
		First Named Inventor	Maria PRAT QUINONES
		Art Unit	
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	09757.0007

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NR/		US-3,714,357	01/30/1973	Gueremy et al.	

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁵
/NR/		CA 2,155,320	08/19/1993	Fujisawa Pharmaceutical Co., Ltd.		
/NR/		EP 0 424 021 A1	4/24/1991	Pfizer Ltd.		
/NR/		EP 0 747 355 A1	12/11/1996	Yamanouchi Pharmaceutical Co., Ltd.		
/NR/		EP 0 801 067 A1	10/15/1997	Yamanouchi Pharmaceutical Co., Ltd.		
/NR/		EP 0 863 141 A1	09/09/1998	Banyu Pharmaceutical Co., Ltd.		
/NR/		EP 0 930 298 A1	07/21/1999	Banyu Pharmaceutical Co., Ltd.		
/NR/		FR 2 012 964	03/27/1970	Societe Generale de Recherches & D'Applications Scientifiques		
/NR/		JP 09-328469	12/22/1997	Fujisawa Pharmaceutical Co., Ltd.		Abstract
/NR/		WO01/04118 A2	01/18/2001	Almirall Prodesfarma SA		
/NR/		WO02/053564 A2	07/11/2002	Almirall Prodesfarma AG		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁵
/NR/		N.N. Godovikov, et al., "Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides", <i>Khim. Farm. Zh.</i> , Vol. 19, No. 9, pp 1060-1061, 1985.	Abstract
/NR/		J. Lars et al., "Some quinuclidine derivatives with potential antimalarial activity", <i>Acta Pharm. Suecica</i> , Vol. 5, pp. 71-76, 1968.	
/NR/		L. Noronha-Blob et al., "Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate", <i>European Journal of Pharmacology</i> , Vol. 221, pp. 97-103, 1992.	
/NR/		S.H. Gao et al., "Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit", <i>Chemical Journal of Chinese Universities</i> , Vol. 20, No. 2, pp. 232-236, 1999.	Abstract

Examiner Signature	/Nilofar Rahmani/	Date Considered	11/29/2007
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		Application Number	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	December 20, 2004
		First Named Inventor	Maria PRAT QUINONES
		Art Unit	
		Examiner Name	
		Attorney Docket Number	09505.0007
Sheet	1	of	1

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ³
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
/NR/		WO02/051841 A1	07/04/2002			
/NR/		WO02/00652 A1	01/03/2002			abstrat

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ³
/NR/		PCT International Search Report dated December 5, 2003	

Examiner Signature	/Niloofer Rahmani/	Date Considered	11/29/2007
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS Form PTO/SB/08: Substitute for form 14-9A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/518,496
		Filing Date	December 20, 2004
		First Named Inventor	Maria Prat Quinones
		Art Unit	1614
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	09757.0007-00000	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
/NR/	1	2,762,796	9/11/1956	Morel et al.	
/NR/	2	US-2004/0063950	4/1/2004	Farrerons Gallemi et al.	
/NR/	3	US-2004/0235887	11/25/2004	Farrerons Gallemi et al.	
/NR/	4	US-2004/0242629 A1	12/2/2004	Buil Albero et al.	
/NR/	5	US-2004/0266816 A1	12/30/2004	Buil Albero et al.	
/NR/	6	US-2005/0043349	2/24/2005	Catena Ruiz et al.	
/NR/	7	US-6,916,828 B2	7/12/2005	Farrerons Gallemi et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
/NR/	8	GB 1 246 606	7/12/2005	Stargardzkie Zaklady		
/NR/	9	WO 03/053966 A2	7/3/2003	Laboratorios SALVAT, SA		
/NR/	10	WO 2004/000840	12/31/2003	Almirall Prodesfarma AG		
/NR/	11	WO 2004/005285	1/15/2004	Almirall Prodesfarma AG		
/NR/	12	WO 93/15080	8/5/1993	Smithkline Beecham		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation
/NR/	13	Abstract for Wallis, R.M. & Napier, C.M. Life Sci. 64(6-7):395-401 (1996) PMID 10069502.		
/NR/	14	Abstract for White, M.V. J. Allergy Clin. Immunol. 95(5 pt 2): 1065-68 (1995) PMID 7751523.		
/NR/	15	Brown, J.H. and Taylor, P. (2001) "Muscarinic Receptor Agonists and Antagonists, " Chapter 7 in The Pharmacological Basis of Therapies. Goodman et al. eds., McGraw Hill: 10th edition, pp. 155-173.		
/NR/	16	Eglen, R.M. and Hedge, S.S. (1997) "Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential," Drug News Perspect. 10(8): 462-469.		

Examiner Signature	/Niloofer Rahmani/	Date Considered	11/29/2007
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Application Number 10/518,496
Filing Date December 20, 2004
First Named Inventor Maria Prat Quinones
Art Unit 1614
Examiner Name
Attorney Docket Number 09757.0007-00000

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
/NR/	17	Eglen, R.M. et al. "Therapeutic opportunities from muscarinic receptor research," TRENDS in Pharm. Sci. 22(8), August 2001, 409-414.	
/NR/	18	Fryer et al., <i>Am. J. Respir. Crit. Care Med.</i> 158:S154-S160 (1998)	
/NR/	19	Interview Summary dated January 19, 2006, from US Application No. 10/404,395.	
/NR/	20	Interview Summary/Office Action dated February 28, 2005, from US Application No. 10/404,395.	
/NR/	21	Interview Summary/Office Action dated February 28, 2005, in U.S. Application No. 10/193,622.	
/NR/	22	Konzett, H. and Rossler, R. (1940). "Versuchsanordnung zu Untersuchungen an der Brochialmuskulatur," <i>Arch. Exp. Path. Pharmacol.</i> 195: 71-74.	
/NR/	23	Notice of Allowance/Notice of Allowability, dated January 19, 2006, from US Application No. 10/404,395	
/NR/	24	Office Action dated February 3, 2005, from US Application No. 10/404,395.	
/NR/	25	Office Action dated February 3, 2005, in U.S. Application No. 10/193,622.	
/NR/	26	Office Action dated May 18, 2005, from US Application No. 10/404,395.	
/NR/	27	Office Action dated May 18, 2005, in U.S. Application No. 10/193,622.	
/NR/	28	Office Action dated November 1, 2005, in U.S. Application No. 10/193,622.	
/NR/	29	Rang, H.P. et al. (1995). "Cholinergic Transmission," Chapter 6 in <i>Pharmacology</i> . Churchill Livingstone, New York, NY. 3rd Edition, pp. 117-147.	
/NR/	30	Ringdahl, R. et al. (1979). "Facile Preparation of the Enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol," <i>Acta Pharm Suec.</i> 16: 281-283.	
/NR/	31	Saraswati, M. et al. (1994). "Structure Activity Studies of N,N-Dialkyl and Cycloalkyl Carbamate Esters of Dimethylethanolamine and Choline with Nicotine and Muscarinic Cholinergic Properties," <i>Drug Development Research</i> 31: 142-146.	
/NR/	32	Shutske, G.M. (1990) "A Novel Synthesis of the Isoxazol[5,4,3-kl]-acridine Ring System," <i>J. Heterocyclic Chem.</i> 27: 1617-1621.	
/NR/	33	van Zwieten et al. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 1995, 9(1): 159-67.	
/NR/	34	Waelbroeck, M. et al. (1990). "Binding of Selective Antagonists to Four Muscarinic Receptors (M1 to M4) in Rat Forebrain," <i>Molecular Pharmacology</i> . 38:267-273.	
/NR/	37	Xu et al. <i>Chemical & Pharmaceutical Bulletin</i> , 1998, 46(2): 231-241.	
/NR/	38	Notice of Allowance/Notice of Allowability, dated May 25, 2006, from US Application No. 10/193,622	
/NR/	39	Office Action dated July 13, 2006, from US Application No. 10/404,395.	

Examiner Signature	/Niloofer Rahmani/	Date Considered	11/29/2007
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.